stockrowAvalo Therapeutics, Inc.
AVTX Healthcare Biotechnology
Avalo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $59,000.00, down 86.6% from fiscal 2024.
- Revenue
- −70.1%
- EPS
- +56.8%
- Free cash flow
- +75.7%
Quarter to June 2026, against a year earlier
Follow AVTX
Alert me
Avalo Therapeutics, Inc. (AVTX) EV/Sales
As of 6 November 2026, Avalo Therapeutics, Inc. (AVTX) trades at a EV/Sales of −68.8×. Over the past ten years it has ranged from −1,782× (December 2019) to 414× (August 2026); the current reading is higher than 2% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 126× | — |
| FY2024 | −37.5× | — |
| FY2023 | 5.8× | 115.94% |
| FY2022 | 2.7× | (90.37%) |
| FY2021 | 27.9× | 15.17% |
| FY2020 | 24.2× | (30.98%) |
| FY2019 | 35.1× | 108.67% |
| FY2018 | 16.8× | 678.03% |
| FY2017 | 2.2× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | −37.5× | — |
| Sep 2024 | −10.4× | — |
| Dec 2023 | 5.8× | 89.75% |
| Sep 2023 | 3.1× | 411.01% |
| 29 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AVTX Avalo Therapeutics, Inc. | −68.8× |
| ZURA Zura Bio Limited compare | n/m |
| CTNM Contineum Therapeutics, Inc. compare | n/m |
| RZLT Rezolute, Inc. compare | n/m |
| AGMB AgomAb Therapeutics NV compare | n/m |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| CCCC C4 Therapeutics, Inc. compare | 7.4× |
| LYEL Lyell Immunopharma, Inc. compare | 12,336× |
| TRXB TRex Bio Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)